Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences

Gene Therapy

Volumn 12, Issue 8, 2005, Pages 715-723

  Martin F ^a   Toscano, M Ga ^b   Blundell, M ^c   Frecha, C ^a   Srivastava, G K ^b   Santamaria M ^d   Thrasher, A J ^c   Molina, I J ^b  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Allospecific T cells; Hematopoietic specific; Herpesvirus saimiri; Lentiviral vectors; Transcriptional targeting; WASP gene promoter; Wiskott Aldrich syndrome

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; LENTIVIRUS VECTOR; WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC CELL; HERPES VIRUS SAIMIRI; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WISKOTT ALDRICH SYNDROME;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 2, SAIMIRIINE; HUMANS; MICE; MICE, INBRED BALB C; PROMOTER REGIONS (GENETICS); PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

HERPESVIRIDAE; SAIMIRI; SAIMIRIINE HERPESVIRUS 2; VESPIDAE;

EID: 17644377890     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302457     Document Type: Article

References (41)

1. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
2. Gaspar HB et al. Successful gene therapy of SCID-X1 using a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
3. Aiuti A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
4. Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature 2003; 422: 901-904.
5. Lagasse E et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6: 1229-1234.
6. Camargo FD et al. Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates. Nat Med 2003; 9: 1520-1527.
7. Krause DS et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105: 369-377.
8. Orkin SH, Zon LI. Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nat Immunol 2002; 3: 323-328.
9. Almeida-Porada G et al. Formation of human hepatocytes by human hematopoietic stem cells in sheep. Blood 2004; 104: 2582-2590.
10. Jang YY et al. Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol 2004; 6: 532-539.
11. Zufferey R et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
12. Moreau-Gaudry F et al. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 2001; 98: 2664-2672.
13. + cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 2003; 101: 3416-3423.
14. Cui Y et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002; 99: 399-408.
15. Snapper SB, Rosen FS. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol 1999; 17: 905-929.
16. Thrasher AJ. WASp in immune-system organization and function. Nat Rev Immunol 2002; 2: 635-646.
17. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 78: 635-644.
18. Wengler GS et al. High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome. Blood 1995; 86: 3648-3654.
19. Greer WL et al. Identification of WASP mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome. Hum Genet 1996; 98: 685-690.
20. Shcherbina A, Rosen FS, Remold-O'Donnell E. WASP levels in platelets and lymphocytes of Wiskott-Aldrich syndrome patients correlate with cell dysfunction. J Immunol 1999; 163: 6314-6320.
21. Imai K et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103: 456-464.
22. Stewart DM et al. Studies of the expression of the Wiskott-Aldrich syndrome protein. J Clin Invest 1996; 97: 2627-2634.
23. Parolini O et al. Expression of Wiskott-Aldrich syndrome protein (WASP) gene during hematopoietic differentiation. Blood 1997; 90: 70-75.
24. Petrella A et al. A 5′ regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells. Blood 1998; 91: 4554-4560.
25. Molina IJ et al. T cell lines characterize events in the pathogenesis of the Wiskott-Aldrich syndrome. J Exp Med 1992; 176: 867-874.
26. Gallego MD et al. Defective actin reorganization and polymerization of Wiskott-Aldrich T-cells in response to CD3-mediated stimulation. Blood 1997; 90: 3089-3097.
27. Toscano MG et al. Efficient lentiviral transduction of herpesvirus saimiri immortalized T cells as a model for gene therapy in primary immunodeficiencies. Gene Therapy 2004; 11: 956-961.
28. Demaison C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
29. Ariga T et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J Immunol 2001; 166: 5245-5249.
30. Wada T et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci USA 2001; 98: 8697-8702.
31. Konno A et al. Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood 2004; 103: 676-678.
32. Strom TS et al. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein. Gene Therapy 2003; 10: 803-809.
33. Lutskiy MI et al. Wiskott-Aldrich syndrome in a female. Blood 2002; 100: 2763-2768.
34. Baum C et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
35. Wengler G et al. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood 1995; 85: 2471-2477.
36. Snapper SB et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 1998; 9: 81-91.
37. Hagemann TL, Kwan SP. The identification and characterization of two promoters and the complete genomic sequence for the Wiskott-Aldrich syndrome gene. Biochem Biophys Res Commun 1999; 256: 104-109.
38. Hagemann TL, Mares D, Kwan S. Gene regulation of Wiskott-Aldrich syndrome protein and the human homolog of the Drosophila Su(var)3-9: WASP and SUV39H1, two adjacent genes at Xp11.23. Biochim Biophys Acta 2000; 1493: 368-372.
39. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541-7547.
40. Hacein-Bey-Abina S et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
41. Neil S et al. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 2001; 75: 5448-5456.